References
- Silberstein SD, Winner PK, Chmiel JJ. Migraine preventive medication reduces resource utilization. Headache43, 171–178 (2003).
- Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet358, 1668–1675 (2001).
- Gallagher R. What do patients want from acute migraine treatment? Cephalalgia24(Suppl. 2), 8–15 (2004).
- Ferrari MD, Goadsby PJ, Lipton RB et al. The use of multiattribute decision models in evaluating triptan treatment options in migraine. J. Neurol.252, 1026–1032 (2005).
- Daez FI, Straube A, Zanchin G. Patient preference in migraine therapy. A randomized, open-label, crossover clinical trial of acute treatment of migraine with oral almotriptan and rizatriptan. J. Neurol.254, 242–249 (2007).
- Mathew NT. Efficacy and tolerability of almotriptan in controlled clinical trials. Eur. Neurol.53(Suppl. 1), 29–33 (2005).
- Pascual J. Efficacy and tolerability of almotriptan in post-marketing surveillance studies. Eur. Neurol.53(Suppl. 1), 34–40 (2005).
- Mathew NT, Finlayson G, Smith TR et al. Early intervention with almotriptan: results of the AEGIS trial (Axert Early Migraine Intervention Study). Headache47, 189–198 (2007).
- Freitag FG, Finlayson G, Rapoport et al. Effect of pain intensity and time to administration on responsiveness to almotriptan: results from the Axert 12.5 mg Time Versus Intensity Migraine Study (AIMS). Headache47, 519–530 (2007).
- Lainez M. Clinical benefits of early triptan therapy for migraine. Cephalalgia24(Suppl. 2), 24–30 (2004).
- Kelman L, Von Seggern RL. Using patient-centered endpoints to determine the cost–effectiveness of triptans for acute migraine therapy. Am. J. Ther.13, 411–417 (2006).
- Williams P, Reeder CE. A comparison of the cost–effectiveness of almotriptan and sumatriptan in the treatment of acute migraine using a composite efficacy/tolerability end point. J. Manag. Care Pharm.10, 259–265 (2004).
- Gori S, Morelli N, Acuto G et al. A pharmacoeconomic evaluation of oral triptans in the treatment of migraine in Italy. Minerva Med.97, 467–477 (2006).
- Mullins CD, Subedi PR, Healey PJ, Sanchez RJ. Economic analysis of triptan therapy for acute migraine: a Medicaid perspective. Pharmacotherapy27, 1092–1101 (2007).
- Lainez MJ, Galavan J, Heras J, Vila C. Crossover, double-blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapy. Eur. J. Neurol.14, 269–275 (2007).
- Lofland JH, Nash DB. Oral serotonin receptor agonists: a review of their cost effectiveness in migraine. Pharmacoeconomics23, 259–274 (2005).
- McCormack PL, Foster RH. Rizatriptan: a pharmacoeconomic review of its use in the acute treatment of migraine. Pharmacoeconomics23, 283–298 (2005).
- Vicente-Herrero T, Burke TA, Laínez MJ. The impact of a worksite migraine intervention program on work productivity, productivity costs, and non-workplace impairment among Spanish postal service employees from an employer perspective. Curr. Med. Res. Opin.20(11), 1805–1814 (2004).